- Home
- BVN vs ICUI Comparison
BVN vs ICUI Comparison
Compare BVN & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BVN
- ICUI
- Stock Information
- Founded
- BVN 1953
- ICUI 1984
- Country
- BVN Peru
- ICUI United States
- Employees
- BVN N/A
- ICUI N/A
- Industry
- BVN Metal Mining
- ICUI Medical/Dental Instruments
- Sector
- BVN Basic Materials
- ICUI Health Care
- Exchange
- BVN Nasdaq
- ICUI Nasdaq
- Market Cap
- BVN 4.2B
- ICUI 3.4B
- IPO Year
- BVN 1996
- ICUI 1992
- Fundamental
- Price
- BVN $16.40
- ICUI $127.56
- Analyst Decision
- BVN Buy
- ICUI Strong Buy
- Analyst Count
- BVN 2
- ICUI 5
- Target Price
- BVN $16.75
- ICUI $196.75
- AVG Volume (30 Days)
- BVN 757.5K
- ICUI 216.4K
- Earning Date
- BVN 07-24-2025
- ICUI 08-06-2025
- Dividend Yield
- BVN 1.78%
- ICUI N/A
- EPS Growth
- BVN 2751.76
- ICUI N/A
- EPS
- BVN 1.90
- ICUI N/A
- Revenue
- BVN $1,215,528,000.00
- ICUI $2,420,093,000.00
- Revenue This Year
- BVN $11.64
- ICUI N/A
- Revenue Next Year
- BVN $9.23
- ICUI N/A
- P/E Ratio
- BVN $8.78
- ICUI N/A
- Revenue Growth
- BVN 37.33
- ICUI 7.22
- 52 Week Low
- BVN $11.50
- ICUI $117.92
- 52 Week High
- BVN $17.59
- ICUI $196.26
- Technical
- Relative Strength Index (RSI)
- BVN 51.55
- ICUI 46.67
- Support Level
- BVN $16.10
- ICUI $130.44
- Resistance Level
- BVN $17.18
- ICUI $139.41
- Average True Range (ATR)
- BVN 0.44
- ICUI 4.00
- MACD
- BVN -0.04
- ICUI 0.02
- Stochastic Oscillator
- BVN 44.29
- ICUI 24.29
About BVN Buenaventura Mining Company Inc.
Compania de Minas Buenaventura SAA is a Peruvian precious metals-producing company with experience in mine exploration, development, construction, and operation.
About ICUI ICU Medical Inc.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.